| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Inventory | NaN | NaN | 10,986 | 9,889 |
| Related party receivable | NaN | NaN | NaN | 181 |
| Accounts receivable, net | NaN | NaN | 3,498 | 2,870 |
| Non-trade receivable | NaN | NaN | 9,841 | 6,967 |
| Cash and cash equivalents | 1,195 | 1,303 | 2,137 | 2,006 |
| Receivable for cash held back from the asset sale | 1,500 | NaN | NaN | NaN |
| Prepaid expenses and other current assets | 608 | 676 | 3,839 | 5,210 |
| Current assets held for sale | NaN | 26,930 | NaN | NaN |
| Total current assets | 3,303 | 28,909 | 30,301 | 27,123 |
| Property and equipment, net | NaN | NaN | 140 | 161 |
| Investment in dna x llc under equity method | 1,290 | 1,242 | NaN | NaN |
| Contract fulfillment assets | NaN | NaN | 9,053 | 8,014 |
| Deferred tax assets | NaN | 1,441 | NaN | NaN |
| Other assets | 245 | 274 | 725 | 780 |
| Non-current assets held for sale | NaN | 12,032 | NaN | NaN |
| Total assets | 4,838 | 43,898 | 40,219 | 36,078 |
| Promissory notes, net | NaN | 5,065 | 4,817 | 2,916 |
| Accounts payable | 719 | 4,030 | 20,408 | 20,583 |
| Accrued liabilities | 1,576 | 704 | 13,631 | 12,163 |
| Promissory notes, net | 1,072 | NaN | NaN | NaN |
| Derivative liability | 398 | 171 | NaN | NaN |
| Current liabilities held for sale | NaN | 38,057 | NaN | NaN |
| Income tax payable | 556 | NaN | NaN | NaN |
| Total current liabilities | 4,321 | 48,027 | 38,856 | 35,662 |
| Promissory notes, net | NaN | NaN | 250 | NaN |
| Income tax payable | NaN | 2,598 | 1,814 | 1,750 |
| Deferred tax liability | 600 | NaN | NaN | NaN |
| Total liabilities | 4,921 | 50,625 | 40,920 | 37,412 |
| Redeemable common stock 0.001 par value 223,201 shares issued and outstanding redemption value 900 at march 31, 2026 and 1,228 as of december 31, 2025 (note 6) | 900 | 1,228 | NaN | NaN |
| Common stock, 0.001 par value per share 1,000,000,000 shares authorized and 1,265,067 shares issued and outstanding at both march 31, 2026 and december 31, 2025 | 1 | 1 | 1 | 10 |
| Additional paid-in capital | 296,613 | 296,309 | 294,676 | 289,281 |
| Accumulated deficit | -297,597 | -304,265 | -295,378 | -290,625 |
| Total stockholders deficit | -983 | -7,955 | -701 | -1,334 |
| Total liabilities, redeemable common stock, and stockholders deficit | 4,838 | 43,898 | 40,219 | 36,078 |
DNA X, Inc. (SONM)
DNA X, Inc. (SONM)